Nasdaq Moves to Delist Silexion Therapeutics
SLXN is trading near its 52-week low of $0.373 (3.4% above the low).
Summary
Silexion Therapeutics received a Nasdaq delisting notice for failing to meet the minimum shareholders' equity requirement. The company plans to appeal by August 25, 2026, but a mandatory monitor limits its options.
Key Events · Legal and Risk Events · SLXN
-
Nasdaq Delisting Notice Received
On August 18, 2026, Nasdaq issued a delisting notice for non-compliance with the minimum shareholders' equity requirement of $2.5 million under Rule 5550(b)(1).
-
Equity Deficiency
The company reported shareholders' equity of only $44,000 as of June 30, 2026, far below the required minimum.
-
Mandatory Panel Monitor
A Mandatory Hearings Panel Monitor is in effect, preventing Nasdaq from granting additional time to regain compliance.
-
Appeal Deadline
The company intends to request an appeal before a Nasdaq Hearings Panel by August 25, 2026.
Analysis · SLXN · Life Sciences
A formal delisting notice from Nasdaq landed on August 18, 2026, after Silexion Therapeutics reported shareholders' equity of just $44,000 against a $2.5 million minimum. With a Mandatory Hearings Panel Monitor in place, Nasdaq has no discretion to grant additional time, leaving the appeal as the company's only route to remain listed. Should the appeal fail, trading in both ordinary shares and warrants will be suspended and the securities removed from Nasdaq.
At the time of this filing, SLXN was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.37 to $80.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.